• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Soligenix Inc.

    5/5/25 4:09:41 PM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNGX alert in real time by email
    DEFA14A 1 tm252585d3_defa14a.htm DEFA14A

     

     

     

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

    Filed by the Registrant x

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement

    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ¨ Definitive Proxy Statement

    x Definitive Additional Materials

    ¨Soliciting Material Pursuant to §240.14a-12

     

    SOLIGENIX, INC.

    (Name of Registrant as Specified in Its Charter)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x No fee required.

     

    ¨ Fee paid previously with preliminary materials.

     

    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

     

     

     

     

     

     

    GRAPHIC

    Your Vote Counts! SOLIGENIX, INC. 29 EMMONS DRIVE SUITE B-10 PRINCETON, NJ 08540 SOLIGENIX, INC. 2025 Annual Meeting Vote by June 19, 2025 11:59 PM ET You invested in SOLIGENIX, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 20, 2025. Vote Virtually at the Meeting* June 20, 2025 9:00 AM, EDT Virtually at: www.virtualshareholdermeeting.com/SNGX2025 *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V74984-P29081 Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 6, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

    GRAPHIC

    THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V74985-P29081 1. To elect five directors to serve until the next Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified. For All Nominees: 01) Christopher J. Schaber, Ph.D. 02) Gregg A. Lapointe, C.P.A. 03) Diane L. Parks, M.B.A. 04) Robert J. Rubin, M.D. 05) Jerome B. Zeldis, M.D., Ph.D. 2. To approve the 2025 Equity Incentive Plan. For 3. To hold an advisory vote on executive compensation. For 4. To ratify the appointment of Cherry Bekaert LLP as our independent registered public accounting firm for the year ending December 31, 2025. For 5. To approve an adjournment of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation of proxies in the event there are not sufficient shares voted to constitute a quorum or votes in favor of a particular proposal for approval. For NOTE: To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.

    Get the next $SNGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNGX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNGX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Soligenix Inc.

      DEFA14A - SOLIGENIX, INC. (0000812796) (Filer)

      5/5/25 4:09:41 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Soligenix Inc.

      DEF 14A - SOLIGENIX, INC. (0000812796) (Filer)

      5/5/25 4:05:36 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soligenix Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - SOLIGENIX, INC. (0000812796) (Filer)

      3/28/25 4:05:36 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNGX
    Financials

    Live finance-specific insights

    See more
    • Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 20, 2024 / RedChip Companies will air interviews with Nova Minerals Limited (NASDAQ:NVA) and Soligenix Inc. (NASDAQ:SNGX) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 21, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nova Minerals: https://www.redchip.com/assets/access/nva_accessSoligenix: https://www.redchip.com/assets/access/sngx_accessChristopher Gerteisen, CEO of Nova Minerals, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Nova Minerals p

      9/20/24 9:00:00 AM ET
      $BOXL
      $NVA
      $SNGX
      Other Consumer Services
      Real Estate
      Precious Metals
      Basic Materials
    • Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / August 16, 2024 / RedChip Companies will air interviews with Soligenix Inc. (NASDAQ:SNGX) and American Resources Corp. (NASDAQ:AREC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessAmerican Resources: https://www.redchip.com/assets/access/arec_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and CEO of Soligenix, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV

      8/16/24 9:00:00 AM ET
      $AREC
      $SNGX
      Coal Mining
      Energy
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Sharps Technology Inc. (NASDAQ:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessSharps Technology: https://www.redchip.com/assets/access/stss_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, appears on the RedChip Small Stocks Big Money™ show on B

      6/7/24 9:00:00 AM ET
      $SNGX
      $STSS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments

    $SNGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders

      PRINCETON, N.J., Sept. 22, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on September 21, 2023 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the "SEC") on August 7, 2023 (the "Proxy Statement"). As a result of the additional ti

      9/22/23 4:00:00 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors

      Strengthens regulatory and orphan drug development expertise PRINCETON, N.J., May 3, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Timothy R. Coté, M.D., M.P.H. to its Board of Directors.  Dr. Coté is a leading national regulatory expert in orphan drug development. With 23 years of Federal service at the U.S. Food and Drug Administration (FDA), National Institu

      5/3/23 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting

              - Meeting adjourned to October 19, 2022, at 9:00 a.m., Eastern Time - Soligenix encourages all stockholders of record at the close of business on July 25, 2022 who have not yet voted, to vote by 11:59 p.m., Eastern Time on October 18, 2022 PRINCETON, N.J., Sept. 23, 2022 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2022 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on September 22, 2022 has been partially adjourned for the purpose of soliciting add

      9/23/22 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

      PRINCETON, N.J., May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2025. "Our strategic focus remains on advancing our clinical programs, and we anticipate several significant development milestones. These include top-line results in 2026 from our actively enrolling Phase 3 confirmatory study of Hy

      5/9/25 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc.

      AUSTIN, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix Inc. (NASDAQ:SNGX), a late-stage biopharmaceutical company focused on developing and commercializ

      5/7/25 8:00:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

      Interim Results from FDA-Funded Study Reinforces HyBryte's™ Rapid Response and Strong Safety Profile PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today interim results from the ongoing open-label, investigator-initiated study (IIS) evaluating extended HyBryte™ (synthetic hypericin) treatment for up to 54 weeks in patients with early-stage cutaneous T-cell lymphoma (CTCL). Following 18 weeks of treatment, 75% of patients achieved "Treatment Success," reinforcing HyBryte™ as

      4/14/25 7:30:00 AM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Parks Diane L.

      4 - SOLIGENIX, INC. (0000812796) (Issuer)

      12/13/24 5:37:47 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CSO Donini Oreola

      4 - SOLIGENIX, INC. (0000812796) (Issuer)

      12/13/24 4:26:41 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF FINANCIAL OFFICER Guarino Jonathan L.

      4 - SOLIGENIX, INC. (0000812796) (Issuer)

      12/13/24 4:26:12 PM ET
      $SNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care